TY - JOUR
T1 - Reducing Treatment Burden in AMD
AU - Apte, Rajendra S.
N1 - Funding Information:
R.S.A. is supported by NIH grants R01-EY019287-06A1 and P30 EY02687 (Vision Core Grant), Glenn Foundation for Medical Research Award, the Starr Foundation, Jeffrey Fort Innovation Fund, Edward N. and Della L. Thome Foundation Award, and an unrestricted grant from Research to Prevent Blindness, New York, NY, to the Department of Ophthalmology, Washington University School of Medicine, St. Louis, MO. R.S.A. is a founder of Metro International; is on the scientific advisory board of Liberrty Biosecurity; holds equity in EdenRoc Sciences, Ophthotech, and QBio; and is a consultant for Bayer, Novartis, Roche, Ribomic, Casma Therapeutics, Merck, and Mylan.
Publisher Copyright:
© 2020
PY - 2020/3/19
Y1 - 2020/3/19
N2 - VEGF-A antagonists have revolutionized wet AMD treatment. Several challenges remain including high treatment burden requiring repeated intraocular injections for persistent disease. Brolucizumab directly inhibits VEGF-A function, providing visual outcomes comparable to aflibercept (an FDA-approved VEGF-A antagonist). Anatomic retinal outcomes including retinal fluid, a marker of disease activity, favored brolucizumab. To view this Bench to Bedisde, open or download the PDF.
AB - VEGF-A antagonists have revolutionized wet AMD treatment. Several challenges remain including high treatment burden requiring repeated intraocular injections for persistent disease. Brolucizumab directly inhibits VEGF-A function, providing visual outcomes comparable to aflibercept (an FDA-approved VEGF-A antagonist). Anatomic retinal outcomes including retinal fluid, a marker of disease activity, favored brolucizumab. To view this Bench to Bedisde, open or download the PDF.
UR - http://www.scopus.com/inward/record.url?scp=85081669038&partnerID=8YFLogxK
U2 - 10.1016/j.cell.2020.02.028
DO - 10.1016/j.cell.2020.02.028
M3 - Comment/debate
C2 - 32200797
AN - SCOPUS:85081669038
SN - 0092-8674
VL - 180
SP - 1033
JO - Cell
JF - Cell
IS - 6
ER -